{"id":"NCT00174252","sponsor":"Pfizer","briefTitle":"Study Aimed At Improving Height With Genotonorm In Children Born Little And/Or Light With Growth Retardation At The Age","officialTitle":"Evolution of IGF-1 in Children Born Small for Gestational Age and With Growth Retardation, Treated by Genotonorm Especially Evolution After Dose Adaptation.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-02","primaryCompletion":"2009-04","completion":"2009-04","firstPosted":"2005-09-15","resultsPosted":"2010-06-04","lastUpdate":"2010-06-15"},"enrollment":57,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Fetal Growth Retardation"],"interventions":[{"type":"DRUG","name":"Genotonorm (Somatropin)","otherNames":[]}],"arms":[{"label":"Genotonorm (Somatropin)","type":"EXPERIMENTAL"}],"summary":"To estimate the percentage of children with serum IGF-1 \\> 2 standard deviation (compared to a child of the same gender and age and without growth hormone (GH) deficiency) 9 months and 12 months after initiation of GH treatment.","primaryOutcome":{"measure":"Percentage of Children With Insulin Growth Factor-1 (IGF-1) > 2 Standard Deviation (SD) at 9 and 12 Months","timeFrame":"9 and 12 months","effectByArm":[{"arm":"Genotonorm","deltaMin":86,"sd":null}],"pValues":[{"comp":"OG000","p":null},{"comp":"OG000","p":null}]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":22,"countries":["France"]},"refs":{"pmids":[],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6281234&StudyName=Study%20Aimed%20At%20Improving%20Height%20With%20Genotonorm%20In%20Children%20Born%20Little%20And/Or%20Light%20With%20Growth%20Retardation%20At%20The%20Age"]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":57},"commonTop":["Varicella","Bronchitis","Headache","Constipation","Nasopharyngitis"]}}